Literature DB >> 23768634

Oncologic, functional, and complications outcomes of robot-assisted radical cystectomy with totally intracorporeal neobladder diversion.

Stavros I Tyritzis1, Abolfazl Hosseini, Justin Collins, Tommy Nyberg, Martin N Jonsson, Oscar Laurin, Dinyar Khazaeli, Christofer Adding, Martin Schumacher, N Peter Wiklund.   

Abstract

BACKGROUND: Robot-assisted radical cystectomy (RARC) with totally intracorporeal neobladder diversion is a complex procedure that has been reported with good outcomes in small series.
OBJECTIVE: To present complications and oncologic and functional outcomes of this procedure. DESIGN, SETTING, AND PARTICIPANTS: Between 2003 and 2012 in a tertiary referral center, 70 patients were operated on by two experienced robotic surgeons. Data were collected prospectively and reviewed retrospectively. INTERVENTION: RARC with totally intracorporeal modified Studer ileal neobladder formation. OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: The overall outcome of RARC with a totally intracorporeal neobladder was presented by assessing (1) surgical margins, (2) recurrence or cancer-specific death at 24 mo, (3) 30-d and 90-d complications graded according to the modified Clavien-Dindo system, (4) daytime and nighttime continence (no or one pad per day) at 6 and 12 mo, and (5) satisfactory sexual activity or potency at 6 mo and 12 mo. Survival rates were estimated by Kaplan-Meier plots. RESULTS AND LIMITATIONS: Median follow-up of the cohort was 30.3 mo (interquartile range: 12.7-35.6). We recorded negative margins in 69 of 70 patients (98.6%). Clavien 3-5 complications occurred in 22 of 70 patients (31.4%) at 30 d and 13 of 70 (18.6%) at >30 d. At 90 d, the overall complication rate was 58.5%. Clavien <3 and Clavien ≥3 complications were recorded in 15 of 70 patients (21.4%) and 26 of 70 (37.1%), respectively. Kaplan-Meier estimates for recurrence-free, cancer-specific, and overall survival at 24 mo were 80.7%, 88.9%, and 88.9%, respectively. Daytime continence and satisfactory sexual function or potency at 12 mo ranged between 70% and 90% in both men and women. Limitations of this study include its retrospective design, selection bias due to the learning curve phase, and missing data.
CONCLUSIONS: In this expert center for RARC, outcomes after RARC with totally intracorporeal neobladder diversion appear satisfactory and in line with contemporary open series.
Copyright © 2013 European Association of Urology. Published by Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Complications; Continence; Ileal neobladder; Intracorporeal; Potency; Radical cystectomy; Recurrence; Robot assisted; Sexual function; Studer pouch; Surgical margins

Mesh:

Year:  2013        PMID: 23768634     DOI: 10.1016/j.eururo.2013.05.050

Source DB:  PubMed          Journal:  Eur Urol        ISSN: 0302-2838            Impact factor:   20.096


  39 in total

Review 1.  The Role of Robotics in the Invasive Management of Bladder Cancer.

Authors:  Pramit Khetrapal; Wei Shen Tan; Benjamin Lamb; Melanie Tan; Hilary Baker; James Thompson; Ashwin Sridhar; John D Kelly; Tim Briggs
Journal:  Curr Urol Rep       Date:  2017-08       Impact factor: 3.092

2.  Robotic radical cystectomy with intracorporeal neobladder: Initial experience and outcomes.

Authors:  Zulfiqar A Butt; Ellen Forbes; Jeff Zorn; Blair St Martin
Journal:  Can Urol Assoc J       Date:  2015 Mar-Apr       Impact factor: 1.862

3.  Robotic assisted laparoscopic radical cystectomy with stentless intracorporeal modified Ves.Pa neobladder: early experience.

Authors:  Patrick Whelan; Wei Phin Tan; Dimitri Papagiannopoulos; Philip Omotosho; Leslie Deane
Journal:  J Robot Surg       Date:  2017-01-09

4.  Tips and tricks for intracorporeal robot-assisted urinary diversion.

Authors:  J W Collins; A Hosseini; P Sooriakumaran; T Nyberg; R Sanchez-Salas; C Adding; Martin C Schumacher; N P Wiklund
Journal:  Curr Urol Rep       Date:  2014-11       Impact factor: 3.092

Review 5.  Current Status of Robot-Assisted Radical Cystectomy and Intracorporeal Urinary Diversion.

Authors:  Raj Kurpad; Michael Woods; Raj Pruthi
Journal:  Curr Urol Rep       Date:  2016-06       Impact factor: 3.092

6.  Feasibility of expert and crowd-sourced review of intraoperative video for quality improvement of intracorporeal urinary diversion during robotic radical cystectomy.

Authors:  Mitchell G Goldenberg; Jamal Nabhani; Christopher J D Wallis; Sameer Chopra; Andrew J Hung; Anne Schuckman; Hooman Djaladat; Siamak Daneshmand; Mihir M Desai; Monish Aron; Inderbir S Gill; Raj Satkunasivam
Journal:  Can Urol Assoc J       Date:  2017-10       Impact factor: 1.862

7.  The morbidity of laparoscopic radical cystectomy: analysis of postoperative complications in a multicenter cohort by the European Association of Urology (EAU)-Section of Uro-Technology.

Authors:  Simone Albisinni; Marco Oderda; Laurent Fossion; Virginia Varca; Jens Rassweiler; Xavier Cathelineau; Piotr Chlosta; Alexandre De la Taille; Franco Gaboardi; Thierry Piechaud; Peter Rimington; Laurent Salomon; Rafael Sanchez-Salas; Jens-Uwe Stolzenburg; Dogu Teber; Roland Van Velthoven
Journal:  World J Urol       Date:  2015-07-02       Impact factor: 4.226

Review 8.  SIU-ICUD consultation on bladder cancer: treatment of muscle-invasive bladder cancer.

Authors:  Jeffrey J Leow; Jens Bedke; Karim Chamie; Justin W Collins; Siamak Daneshmand; Petros Grivas; Axel Heidenreich; Edward M Messing; Trevor J Royce; Alexander I Sankin; Mark P Schoenberg; William U Shipley; Arnauld Villers; Jason A Efstathiou; Joaquim Bellmunt; Arnulf Stenzl
Journal:  World J Urol       Date:  2019-01-25       Impact factor: 4.226

Review 9.  Current evidence for robotic surgery in radical cystectomy.

Authors:  Chi Hang Yee; Jeremy Yuen-Chun; Eddie Shu-Yin Chan
Journal:  Turk J Urol       Date:  2020-09-22

Review 10.  Is robotic-assisted radical cystectomy (RARC) with intracorporeal diversion becoming the new gold standard of care?

Authors:  Hitendra R H Patel; Pedro Bargão Santos; Manuel Castanheira de Oliveira; Stig Müller
Journal:  World J Urol       Date:  2015-11-25       Impact factor: 4.226

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.